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Abstract
Background: Metastasis to the bone is one clinically important features of prostate cancer (PCa). Current diagnostic
methods cannot predict metastatic PCa at a curable stage of the disease. Identification of metabolic pathways involved in
the growth of bone metastases therefore has the potential to improve PCa prognostication as well as therapy.
Methodology/Principal Findings: Metabolomics was applied for the study of PCa bone metastases (n=20) in comparison
with corresponding normal bone (n=14), and furthermore of malignant (n=13) and benign (n=17) prostate tissue and
corresponding plasma samples obtained from patients with (n=15) and without (n=13) diagnosed metastases and from
men with benign prostate disease (n=30). This was done using gas chromatography-mass spectrometry for sample
characterization, and chemometric bioinformatics for data analysis. Results were verified in a separate test set including
metastatic and normal bone tissue from patients with other cancers (n=7). Significant differences were found between PCa
bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary
tumor tissue and in plasma which were significantly associated with metastatic disease. Among the metabolites in PCa bone
metastases especially cholesterol was noted. In a test set the mean cholesterol level in PCa bone metastases was
127.30 mg/g as compared to 81.06 and 35.85 mg/g in bone metastases of different origin and normal bone, respectively
(P=0.0002 and 0.001). Immunohistochemical staining of PCa bone metastases showed intense staining of the low density
lipoprotein receptor and variable levels of the scavenger receptor class B type 1 and 3-hydroxy-3-methylglutaryl-coenzyme
reductase in tumor epithelial cells, indicating possibilities for influx and de novo synthesis of cholesterol.
Conclusions/Significance: We have identified metabolites associated with PCa metastasis and specifically identified high
levels of cholesterol in PCa bone metastases. Based on our findings and the previous literature, this makes cholesterol a
possible therapeutic target for advanced PCa.
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Introduction
Aggressive prostate cancer (PCa), eventually spreading to the
bone, is a common and fatal disease requiring early diagnosis and
effective treatment. Current diagnostic methods; measuring levels
of prostate specific antigen (PSA) in blood samples and examining
needle biopsies from the prostate under light microscopy, are
however not particularly effective in separating cases of aggressive
PCa from the even more prevalent and indolent forms of PCa that
often can be left without treatment, or in separating cancer from
other non-malignant prostate disorders [1,2]. Using a variety of
techniques multiple investigators have therefore tried to find novel
diagnostic methods and prognostic markers that can separate
aggressive from more indolent forms of PCa (reviewed in [3]).
Much effort has been put into the recognition of genetic and
proteomic profiles for PCa (reviewed in [4]), and magnetic resonance
spectroscopy have been used to exploit metabolic changes associated
with PCa [5,6,7]. Zakian and colleauges provide a good review on the
subject [8]. In a recent paper, however, Sreekumar and colleagues
used liquid and gas chromatography – time of flight mass
spectrometry (GC/TOFMS) to profile the metabolome in tissue,
urine, and plasma from PCa patients and identified alterations
associated with disease progression [9]. Specifically, they identified
sarcosine, the N-methyl derivative of glycine, as a potentially
important marker for PCa cell invasion, migration, and aggressive-
ness. The Sreekumar study together with other recent studies
[10,11,12,13] truly indicate that mass spectrometry based methods
could be used to characterize metabolomic changes during cancer
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biomarkers or biomarker patterns as well as increase our knowledge
about disease progression.
This study was made with the hypothesis that potential novel
markers for aggressive PCa could be discovered by finding factors
markedly up-regulated in bone metastases and then examine if the
same factors are also increased in blood samples and in primary
tumors frompatients with metastatic disease. We therefore performed
a metabolomic study of PCa bone metastases in comparison with
corresponding normal bone, primary PCa tumor and normal
prostate tissue, using metastatic tissue collected at surgery for
complications of bone metastases [14]. Furthermore, we analyzed
blood samples from patients with and without diagnosed bone
metastases, with the aim to identify metabolites that could be used to
improve prognostication and therapy of advanced PCa. Results were
verified in a separate test set also including metastatic bone tissue
from other cancers. This was done using gas chromatography-mass
spectrometry for sample characterization and chemometric bioinfor-
matics for data analysis and evaluation [15].
Results
Prostate cancer bone metastases show clear metabolic
differences to normal bone and to bone metastases from
other cancers, including increased levels of cholesterol
Gas chromatography-time of flight mass spectrometry (GC/
TOFMS) was used to characterize PCa bone metastases from 14
patients (7 hormone-naive PCa patients and 7 patients with
CRPC) and adjacent normally appearing bone pieces that were
available from 10 of the patients (Table 1). In total, 123
chromatographic peaks corresponding to putative metabolites
were found by deconvolution [16] after exclusion of peaks
originating from internal standards, contamination and artefacts.
Of the 123 putative metabolites, 49 could be assigned an identity
by their mass spectra and corresponding retention index (Figure 1).
Orthogonal partial least squares discriminate analysis (OPLS-DA)
revealed an evident and statistically significant separation
(P,0.001) between the normal bone and bone metastasis samples,
independent of treatment, determined by ANOVA of the cross-
validated model (Figure 2b). Significant differences between the
sample groups (VIP.0.9, Variable importance in OPLS-DA
model or P,0.05, Mann Whitney U-test) were found for 58.5%
(71 of 123) of the putative metabolites (Figure 2a, Table S1). Of
the 71 significantly discriminating metabolites, 34 could be
assigned an identity by their mass spectra and corresponding
retention index, whereas 37 were only assigned to a possible
compound class or remained unidentified. To validate the
detected metabolomic signature in bone metastatic tissue and to
investigate if a unique metabolite pattern for PCa exists, a set of
additional samples were profiled in a separate run. This ‘test set’
included bone metastasis samples from prostate (6), breast (3),
kidney (2) and squamous cell (2) adenocarcinomas as well as
normal bone samples from corresponding patients prepared,
profiled and predicted as a separate validation cohort (Table 1).
Prediction of the PCa bone metastases and corresponding normal
bone samples (blind to the model) into the OPLS-DA model
revealed a clear discrimination between the sample classes in the
test set (Figure 2c). In addition, a separate OPLS-DA model gave a
significant difference (P,0.001) between the PCa bone metastases
and corresponding normal bone samples in the test set and the
metabolites significantly separating those sample groups (Table S2)
overlapped to great extent with the significant metabolites detected
in the model set (Table S1). Furthermore, OPLS-DA exposed an
evident and significant (P,0.005) separation between the PCa
bone metastases and the metastases from the other cancers (Figure
S1).
Table 1. Clinical characteristics of patients operated for complications of bone metastases and included in model and test set of
GC-MS analysis of bone metastases and corresponding normal bone samples.
Metastases Normal bone Age (Yrs) PSA (ng/ml) Chemo
a Radiation
b
Model
Prostate cancer
Hormone-naı ´ve 7 4 79 (60–85) 130 (21–2500) 0 0
Castration-resistant
c 7 6 69 (60–88) 690 (16–2100) 1 2
Total no. 14 10 73 (60–88) 160 (16–2500) 1 2
Test set
Prostate cancer
Castration-resistant
c 6 4 78 (65–83) 140 (14–5139) 1 1
Breast cancer
Hormone-refractory
d 3 3 62 (43–73) - 2 0
Esophagus 1 1 56 - 1 1
Lung 1 1 76 -
Kidney 2 2 60, 82 - 1
Total no. 13 11 76 (43–82) - 5 2
Samples are grouped according to primary diagnosis. Esophagus, lung and kidney patients were all men and breast cancer patients were women. Continuous values are given
as median (min-max).
aChemotherapy including estracyte, taxotere and tamoxifene prior to surgery.
bRadiation against operation site prior to surgery.
cCastration-resistant patients had disease progression after long-term androgen deprivation therapy including surgical ablation, LHRH/GNRH agonist therapy, and anti-
androgen therapy; bicaglutamide.
dHormone-refractory breast cancer patients had disease progression after long-term estrogen deprivation therapy including tamoxifen.
doi:10.1371/journal.pone.0014175.t001
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(Figure 2a and Table S1) we found increased levels of several
amino acids in comparison with normal bone, indicating high
amino acid metabolism. Consequently, the top 12 canonical
pathways in PCa bone metastases suggested by systems pathway
analysis (Ingenuity Systems, Inc.) were all related to amino acid
synthesis and metabolism (Table S3). Amino acid metabolism was
also the top function listed by Ingenuity pathway analysis for PCa
bone metastases (Table S4). Furthermore, we detected high levels
of cholesterol, myo-inositol-1-phosphate, citric acid, fumarate,
glycerol-3-phosphate, and fatty acids (Table S1), which are related
to molecular and cellular functions within PCa bone metastases as
indicated in Table S4.
We specifically noted the high levels of cholesterol in PCa bone
metastases as cholesterol showed the highest VIP value when
differentiating PCa bone metastases from normal bone tissue
(Table S1, Figure 2a) as well as from other bone metastases (Table
S5). Moreover, cholesterol has been suggested to promote cancer
development and progression (reviewed in [17]), and was therefore
chosen for further analysis. The high cholesterol level in PCa bone
metastases as compared to normal bone (P=3.12E-5, Figure 3a)
was clearly verified in the test set data (P=0.001, Figure 3b).
Interestingly, the cholesterol levels in PCa bone metastases were
high also in comparison with levels in bone metastases from other
cancers (P=0.0002, Figure 3b).
Prostate cancer bone metastases have the machinery for
uptake and de novo synthesis of cholesterol
Cholesterol constitutes a potential therapeutic target and we
therefore wanted to examine possible reasons to the high
cholesterol levels in PCa bone metastases. Cells can obtain
cholesterol by exogenous influx via the low density lipoprotein
receptor (LDL-R), the scavenger receptor class B type 1 (SR-B1) or
by de novo synthesis from acetyl-CoA where the reduction of 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) into mevalo-
nate is considered to be the rate-limiting step [18,19]. Paraffin-
embedded pieces from the PCa metastases included in the GC/
TOFMS analysis were therefore immunostained for LDL-R, SR-
B1 and HMG-CoA reductase. All PCa cases showed strong
homogeneous LDL-R staining of metastatic epithelial cells and
occasionally less intense staining of adjacent stroma cells,
endothelial cells, adipocytes, and bone cells (Figure 3c, Table 2).
The epithelial staining of SR-B1 and HMG-CoA reductase was
more heterogeneous, ranging from weak to intense (Table 2).
Interestingly, HMG-CoA reductase showed particularly intense
staining in endothelial cells, vessel walls, immune cells, and bone
cells (Figure 3e), while SR-B1 showed negative stroma staining
(Figure 3d). Our results show that tumor epithelial cells in PCa
bone metastases possibly synthesize cholesterol de novo via HMG-
CoA reductase, but also that other cell types in the bone
metastases micro-environment express this enzyme possibly
allowing them to provide cholesterol that could be taken up by
tumor epithelial cells through the LDL and SRB-1 receptors
(Figure 3f). There was no obvious relation between the
heterogeneity in SR-B1 and HMG-CoA immunostaining and
the corresponding cholesterol levels in the PCa bone metastases
(data not shown). Interestingly, however, the PCa bone metastases
showed generally stronger immunostaining of LDL-R and SR-B1
than the bone metastases of different origin (Table 2), possibly
contributing to the relatively higher cholesterol levels seen in the
PCa metastases (Fig. 3).
Metabolic differences between primary prostate tumor
tissues from high-risk patients with and without
established bone metastases
Primary PCa tissue obtained from patients with high-risk tumors
(defined as locally advanced or poorly differentiated cancer; stage
T3-4 and/or GS 8-10) with (M1, n=7) or without (M0, n=6)
diagnosed bone metastases were profiled in comparison withbenign
prostate samples (n=17, Table 3). This resulted in 157 putative
metabolite peaks of which 59 could be assigned an identity
(Figure 1). Clear and statistical significant discrimination
(P,0.001), determined by ANOVA of the cross-validated model,
between all three prostate tissue classes (benign, M0, and M1) was
revealed by OPLS-DA modelling (Figure S2). Significant changes
associated with metastatic disease, defined as metabolite changes in
M1 vs. benign and M1 vs. M0 (P,0.05 or VIP.0.9) were detected
for 13 metabolites of which eight were identified(Tables S6 and S7).
Interestingly, four of those were also significantly increased in bone
metastases samples as compared to normal bone; aspargine,
threonine, fumaric acid, and linoleic acid (Table S1).
Distinguishing metabolite profiles in blood plasma from
patients with high risk tumors with and without
established bone metastases
Investigation of the plasma metabolome from PCa patients with
(M1, n=15) and without (M0, n=13) diagnosed bone metastases
and men with benign disease was based on 179 resolved putative
metabolites, and of those 50 could be assigned an identity
Figure 1. Metabolite classification. Identified metabolites are categorized according to chemical class and the number of metabolites per class
significantly associated with metastasis is indicated (P,0.05, Mann Whitney U-test, or VIP.0.9). Classification of metabolites according to chemical
class (human metabolome DB; www.hmdb.ca). n= number of identified metabolites within each metabolite class.
doi:10.1371/journal.pone.0014175.g001
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a significant separation (P,0.003) using OPLS-DA modelling was
obtained for the difference between M1 and benign plasma as well
as between M1 and M0 plasma, determined by ANOVA of the
cross validated models. Twenty-seven metabolites, seven identi-
fied, were found as significantly altered (P,0.05 or VIP.0.9) in
the blood plasma from M1 patients in comparison with patients
with benign (Table S8) and M0 disease (Table S9). Interestingly, of
these 27, four metabolites; glutamic acid, taurine, and phenylal-
anine (elevated in the blood) and stearic acid (decreased in blood)
were also found as metastasis markers in bone (Table S1). A
summary of all identified metabolites in the different sample types
are given in Table S10 and data can be found in a supporting data
file (Data S1).
Sarcosine levels in tissue and plasma samples
Sarcosine levels were measured separately in the samples using
AccQNTag derivatization followed by LC/MS analysis. The
analysis showed an increase of sarcosine in PCa bone metastases
compared to normal bone, while no difference could be observed
compared to bone metastases from other cancers (Figure S3). In
addition, no clear disease progression was seen when comparing
the sarcosine levels between benign prostate and primary prostate
tumor tissue, although the low number (n=5) of primary tumor
extracts available for this analysis did affect the reliability of the
results, and also made a comparison between primary tumor and
bone metastasis tissues unreliable. Comparisons of sarcosine levels
in the blood plasma revealed no significant differences related to
PCa or the presence of bone metastases (data not shown).
Figure 2. Metabolic signature in prostate cancer bone metastases. A) Correlation loadings (p[1]) from OPLS-DA analysis of the significantly
differentiating metabolites (P,0.05, Mann Whitney U-test, or VIP.0.9) between prostate cancer bone metastases and normal bone showing positive
values for metabolites with increased levels in bone metastases and negative values for metabolites with decreased levels in bone metastases.
Classification of non-identified compounds according to chemical class (human metabolome DB; www.hmdb.ca) B) OPLS-DA score plot showing
statistically significant separation (P,0.001) between normal bone and prostate cancer bone metastases. C) Test set predictions of prostate cancer
bone metastases and corresponding normal bone samples (blind to the model) into the OPLS-DA model showing a clear discrimination between the
sample classes based on the detected metabolomic signature.
doi:10.1371/journal.pone.0014175.g002
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(mg cholesterol/g tissue) showing significantly higher levels in prostate cancer (PCa) bone metastases compared to normal bone. B. Box plot for
cholesterol concentration (mg cholesterol/g tissue) in test set showing significantly higher levels in PCa bone metastases compared to normal bone
as well as compared to bone metastases from other cancers; breast, kidney, and squamous cancer (BCa, KCa and SCa). C–E. Immunohistochemical
staining of the low density lipoprotein receptor (LDL-R), the scavenger receptor class B type 1 (SR-B1), and the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase (HMG-CoA red.) in PCa bone metastases showing intense staining and indicating possibilities for influx as well as de novo synthesis of
cholesterol in tumor epithelial cells, as suggested in F. F. Cholesterol influx and synthesis is stimulated by androgen receptor (AR) action partly via
activation of the sterol regulatory element-binding protein (SREBP) and subsequent transcription of LDL-R and HMG-CoA red [24,25] and androgens
could be provided from cholesterol by its conversion in several steps [27,28].
doi:10.1371/journal.pone.0014175.g003
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We here, for the first time, report a comprehensive analysis of
metabolic patterns in PCa bone metastases in comparison to
primary PCa, benign prostate tissue, and normal bone tissue. We
have found metabolites which differentiate PCa bone metastases
from normal bone samples and, furthermore, from bone
metastases of different origin. We also found metabolites which,
in contrast to PSA, showed altered plasma and primary tumor
levels in individuals with metastatic PCa in comparison with
patients with high-risk tumors but without detectable metastases.
One of our most notable findings is high levels of cholesterol in the
PCa bone metastases, which is probably reached by de novo
synthesis of cholesterol in tumor epithelial cells as well as influx of
this metabolite from the surroundings via LDL-R and SR-B1.
Increased bioavailability of cholesterol in tumor cells may have
high biological relevance for bone metastases growth, as cho-
lesterol supplementation has been shown to increase PCa tumor
cell proliferation, migration, and invasion in vitro [20] while
cholesterol targeting induces apoptosis [21], probably by lowering
lipid raft cholesterol content and thereby interfering with growth
factor signalling [21,22]. The prostate gland normally contains
high levels of cholesterol in comparison to other organs and
increased cholesterol levels have previously been associated with
PCa [23]. Further elevation of cholesterol levels in bone metastases
could obviously reflect high demand for membrane biosynthesis in
proliferating cells, but also the fact that cholesterol metabolism is
directly regulated by androgens (reviewed in [24]). Androgens
positively regulate LDL-R gene transcription and also promote
cholesterol synthesis by increasing transcription of HMG-CoA
reductase [25] and thus the rate-limiting conversion of HMG-CoA
to mevalonate [26]. As androgen receptors are expressed and
presumingly active in a majority of bone metastases in CRPC [14],
androgen actions probably contribute to the higher cholesterol
Table 2. Immunohistochemical staining of LDL-R, SR-B1, and HMG-CoA reductase in prostate cancer bone metastases and in bone
metastasis of different origin.
Bone metastases n LDL-R n (%) SR-B1 n (%) HMG-CoA red. n (%)
+ ++ - + ++ + ++
Prostate cancer
Hormone-naı ´ve 7 7 (100) 5 (71) 2 (29) 2 (29) 5 (71)
Castration-resistant 13 13 (100) 7 (54) 6 (46) 8 (62) 5 (38)
Total 20 20 (100)** 12 (60) 8 (40)** 10 (50) 10 (50)
Different origin
a
Total 7 4 (57) 3 (43) 4 (57) 2 (29) 1 (14) 4 (57) 3 (43)
aSamples were grouped according to metastasis origin; prostate cancer or other origin. For further clinical characteristics and treatments, please see Table 1.
**Higher fraction with intensely (++) stained cells as compared with metastases of different origin, P,0.01. For definition of staining intensity, please see Materials and
Methods.
doi:10.1371/journal.pone.0014175.t002
Table 3. Clinical characteristics of patients included in GC-MS analysis of plasma and corresponding prostate biopsy samples.
Plasma Biopsy
b
M1
a M0 Benign M1
a M0 Benign
GS
c
6 24 1
7 23 73
8-10 11 6 2
T
d
T1 42
T2 11 11
T3 10 10 6 5
PSA
e (ng/ml) 37 (4.8–997) 16 (9.9–173) 9.0 (4.2–56) 40 (4.8–695) 17 (14–71) 8.9 (4.2–56)
Age
f (yrs) 68 (48–86) 68 (58–80) 66 (51–77) 68 (61–85) 66 (58–77) 65 (59–77)
Total 15 13 30 7 6 17
Continuous values are given as median (min-max).
aAccording to bone scan.
bNo cancer diagnosis or high grade prostate interneoplasia at biopsy.
cTumor differentiation according to Gleason score (GS).
dClinical tumor stage according to Union Internationale Contre le Cancer.
eSerum PSA at date of blood draw and prostate biopsy.
fAge at date of blood draw and prostate biopsy.
doi:10.1371/journal.pone.0014175.t003
Metabolites in Bone Metastases
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14175levels in PCa metastases as compared to bone metastases of
different origin. Cholesterol in turn possibly contributes to
androgen receptor signalling and thus castration resistant tumor
growth in patients treated with androgen-deprivation therapy, by
its conversion into androgens by metabolic enzymes [27,28].
Accordingly, a Western diet and high serum levels of cholesterol
have been associated with increased PCa risk in a number of
studies [29,30,31], although the results have not been completely
conclusive (reviewed in [17]). Interestingly, a recent study shows a
lower risk of developing high-grade PCa for men with low serum
cholesterol levels [32] and, in line with this, long-term use of
HMG-CoA reductase inhibitors (‘‘statins’’) for prevention of
cardiovascular disease have been shown to reduce the risk of
PCa progression into aggressive, fatal disease [33,34,35,36].
Cholesterol-lowering agents have also been shown to inhibit
growth of PCa cells in vitro and in model experimental systems in
vivo [37,38]. Taken together, those results indicate the possibility of
using cholesterol inhibitors as treatment or chemopreventive
agents for PCa metastasis, but novel drugs are then needed as the
statins used today primarily concentrate to the liver and poorly
reach peripheral organs [17].
We found high levels of many amino acids within the PCa bone
metastases, and amino acid metabolism was the most altered
functional pathway associated with PCa bone metastases accord-
ing to Ingenuity pathway analysis. Our results thus support the
metabolomic-based study by Sreekumar and co-workers [9] and
also earlier gene-expression-based studies showing increased
protein synthesis during PCa progression [39]. Interestingly, a
recent paper high-lighted that also levels of aminoacyl tRNA
synthetases (aaRSs) are increased during PCa progression and,
furthermore, that transcription of some aaRSs is stimulated by
androgens [40]. This remarkable finding could possibly be
connected to the fact that we found increased levels of certain
amino acids such as threonine, glutamate, phenylalanine within
PCa bone metastases in comparison with bone metastases of
different origin. In addition to the amino acids, other notable
metabolites in our data (citric acid, fumarate, glycerol-3-phos-
phate, and fatty acids) indicate a high energy metabolism that
could reflect the high fraction of proliferating cell within bone
metastases [14]. Moreover, the high levels of myo-inositol-1-
phosphate could be a sign of active cell signalling involving
inositol-based molecules as second messengers, such as inositol
phosphates and phosphatidylinositol phosphates. Those molecules
are involved in activating protein kinase C and Akt and thus in
regulating processes considered as hallmarks of cancer, i.e. cell
proliferation, apoptosis, differentiation, invasion, and angiogenesis
[41]. Overall the alterations in the metabolome detected in this
study as associated with PCa bone metastases indicated disturbed
molecular and cellular functions of clear relevance for cancer
progression. The relative importance of those functions are
however difficult to assign, as they partly depend on the metabolite
classes detectable within the GC/TOFMS analysis and the
identities obtained within currently available libraries. With the
GC/TOFMS metabolite profiling method we were not able to
detect sarcosine in the samples. However, using a targeted analysis
approach, we found high levels of sarcosine in bone metastases in
accordance with previous findings of increased levels of sarcosine
with PCa progression [9]. Importantly though, we did not see any
difference in sarcosine levels between PCa bone metastases and
bone metastases of different origin, indicating that sarcosine is not
PCa specific but instead associated with advanced cancer and
metastasis. A more comprehensive picture of specific biological
networks of importance for PCa metastases growth will be
obtained as analysis methods develop and libraries for identifica-
tion get more complete, but could also be achieved by combining
metabolomic data with genomic or proteomic data. So far, we
specifically note that threonine, aspargine, fumaric acid, and
linoleic acid are increased not only in bone metastases but also in
primary prostate tissue from patients with confirmed bone
metastases when compared with M0 patients. Essential fatty acid
such as linoleic acid have been shown to stimulate PCa tumor
growth in model systems [42,43], and the conversion of linoleic
acid to arachidonic acid and further into prostaglandins could
possibly stimulate an inflammatory response which is associated
with pathogenesis of PCa [44].
Neither cholesterol nor sarcosine were, however, prognostic for
bone metastases in plasma. Instead high levels of glutamatic acid,
phenylalanine, and taurine were found in PCa bone metastasis
tissue and in plasma from men with diagnosed PCa bone
metastases. Glutamic acid was recently shown in the study by
Sreekumar and collegues to be increased in PCa tissue [9] and,
interestingly, cancer cells that cause bone disruption in animal
models secrete glutamate into their environment [45]. As
glutamatergic intercellular communication is important for normal
bone homeostasis via glutamate receptors on specific bone cells
(reviewed in [46]) it is possible that disturbances within this system
could be detected during the process of bone metastasis. Our
results are also in line with a recent study that found higher taurine
levels in PCa than in benign tissue when assessed using magic
angle spinning ((1)H HR-MAS) NMR spectroscopy [47]. The
value of these metabolites as plasma markers for aggressive PCa
however needs to be confirmed in further studies.
In conclusion, we have identified metabolites associated with
prostate cancer metastasis and specifically noted high levels of
cholesterol in PCa bone metastases. Based on our findings and the
previous literature, this makes cholesterol a possible therapeutic
target for advanced PCa. Although this is the largest metabolomic
study of PCa bone metastases performed it certainly has its
limitations. Previous
1H NMR studies have revealed evident
changes in levels of citrate and choline between benign prostate
and tumor tissue [5,6,7] but somewhat concerning, we were not
able to find such differences in citrate levels. Neither could we with
our method detect choline. These results do highlight limitations of
our method and point out the need for complementary approaches
in the search for useful metabolomic biomarkers. Furthermore, the
rather low number of patients included and the heterogeneity of
metastatic disease make evaluation in further studies necessary
before the significance of our results could be assured.
Materials and Methods
Ethics statement
Studies were approved by the local ethic review board of Umea ˚
University and participants gave written or verbal consent.
Samples
Bone metastases and adjacent normally appearing bone tissue
pieces were obtained from a series of fresh-frozen biopsies collected
from patients with cancer diagnosis or suspicion of cancer, operated
for metastatic spinal cord compression or pathologic fractures
(Table 1). Patients have been thoroughly described in [14].
Blood plasma was available from a series of men who
underwent transrectal ultrasound–guided needle biopsies of the
prostate, due to increased serum PSA levels, and primary PCa and
benign prostate biopsies were assessable in some cases (Table 3).
The patients included in this study were all selected to have high-
risk tumors defined as; presence of bone metastases or a locally
advanced tumor or a poorly differentiated cancer (M1 and/or T3-
Metabolites in Bone Metastases
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rounds of negative biopsies. The PCa cases and the benign cases
were matched according to time since sampling. Additional
information about patients and sample preparation is given in
supporting text (Text S1).
Metabolomic profiling using GC/TOFMS
Prior to GC/TOFMS analysis the low molecular weight
metabolites in plasma samples were extracted and derivatized as
previously described [48]. Tissue samples were extracted with
H2O/methanol/chloroform (1:3:1) mixture containing 11 internal
standards A [48] (1 mL per 15 mg of tissue) evenly distributed
over the chromatographic retention span. Extraction was carried
on in bead mill with two tungsten beads and the rest of the
procedure was the same as for plasma samples. Derivatized sample
extracts were then injected in splitless mode by an CTC Combi
Pal autosampler (CTC Analytics AG, Zwingen, Switzerland) into
an Agilent 6890 gas chromatograph equipped with a
10 m60.18 mm i.d. fused silica capillary column with a
chemically bonded 0.18 mm DB 5-MS stationary phase (J&W
Scientific, Folsom, CA, USA). The column effluent was introduced
into the ion source of a Pegasus III time-of-flight mass
spectrometer, GC/TOFMS (Leco Corp., St Joseph, MI, USA).
An alkane serie (C10-C40) was run for each separate GC/
TOFMS run. More details regarding sample preparation,
derivatization and GC/TOFMS analyses can be found in the
supplementary information. The reproducibility of the method has
been reported previously [16,48].
Data processing
Data pre-treatment including baseline correction, chromato-
gram alignment, time-window setting, hierarchical multivariate
curve resolution (H-MCR) [11] and normalization were per-
formed in MATLAB [version 7.3] using custom scripts. More
details regarding the data processing can be found in the
supporting information (Text S1).
Data analysis and Statistics
Orthogonal partial least squares - discriminant analysis (OPLS-
DA) [49] was applied to extract and interpret the systematic
variation in the resolved GC/TOFMS tissue and plasma profiles
related to specific responses. The objective was to extract metabolic
patterns related to PCa and more specifically to metastatic disease.
The OPLS-DA variable importance in the projection (VIP) values
combined with univariate p-values (Mann-Whitney U-test) were
used to highlight significant metabolites or metabolite patterns
(VIP.0.9 or P,0.05). ANOVA of the cross-validated models were
used to determine the significance of the extracted metabolite
patterns. Comparisons of categorical data were made using the chi-
square test. For more details see supporting information (Text S1).
Pathway analysis
Differentiating metabolites between PCa bone metastases and
normal bone (VIP.0.9 in OPLS-DA and/or P,0.05 in Mann-
Whitney U-test, were included in pathway analysis according to
Ingenuity Systems, Inc. Top altered canonical pathways and
cellular and molecular functions in bone metastases were listed.
Metabolite identification
Detected peaks were identified by a data base search, based on
spectra and chromatographic retention index, using NIST MS-
Search v. 2.0 [50] with the in-house mass spectra library database
established by Umea ˚ Plant Science Center (UPSC), the mass
spectra library maintained by the Max Planck Institute in Golm
(http://csbdb.mpimp-golm.mpg.de/csbdb/gmd/gmd.html) or the
NIST98 mass spectra library. For a more detailed description, see
supporting text (Text S1).
Immunohistochemistry
Samples were fixed in buffered formalin, decalcified in formic
acid, and embedded in paraffin. Five mm paraffin-embedded
sections were de-paraffinated and rehydrated according to
standard procedures and boiled in 10 mM Tris, 1 mM EDTA
(pH=9) for 1 h in 2100 Retriever (HistoLab, Fro ¨lunda, Sweden).
Primary antibody incubations and secondary systems were as
follows; Anti-LDL receptor (ab52818, Abcam, Cambridge, UK,
diluted 1:250) and Anti-SRB-1 (EP1556Y, Novus Biologicals,
Littleton, CO, diluted 1:50) were visualized using the iVIEW
TM
DAB detection kit (Ventana, Tucson, AZ) while Anti-HMG-CoA
reductase (Upstate, cat 07-457, Millipore, Temecula, CA, diluted
1:250) were incubated over night and further detected using the
ABC Vectastain kit (Vector Laboratories, Burlingame, CA) with
DAB as chromogen. The staining intensity was scored as weak (+)
or intense (++) and for SR-B1 also as negative (-) in a few cases.
Positive controls for the immunostaining assays (liver and ovarian
tissues) showed strong staining and control sections that were
incubated without primary antibodies showed no staining.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0014175.s001 (0.04 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0014175.s002 (0.20 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0014175.s003 (0.09 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0014175.s004 (0.04 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0014175.s005 (0.03 MB
DOC)
Table S5
Found at: doi:10.1371/journal.pone.0014175.s006 (0.07 MB
DOC)
Table S6
Found at: doi:10.1371/journal.pone.0014175.s007 (0.07 MB
DOC)
Table S7
Found at: doi:10.1371/journal.pone.0014175.s008 (0.07 MB
DOC)
Table S8
Found at: doi:10.1371/journal.pone.0014175.s009 (0.06 MB
DOC)
Table S9
Found at: doi:10.1371/journal.pone.0014175.s010 (0.07 MB
DOC)
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14175Figure S1 Multivariate modelling in the search for a unique
metabolite pattern in prostate cancer (PCa) bone metastases.
OPLS-DA score vector (t[1]) showing a clear and significant
difference between PCa bone metastases and bone metastases
from other cancers: breast, kidney, and squamous cancer (BCa,
KCa and SCa).
Found at: doi:10.1371/journal.pone.0014175.s012 (2.24 MB
TIF)
Figure S2 Metabolomic differences between primary prostate
cancer tissues from high-risk patients with (M1) and without (M0)
established bone metastases. OPLS-DA score plot (t[2]/t[1])
revealing clear differences in metabolic signatures in primary
prostate tumor tissue from patients with and without diagnosed
bone metastases compared to benign prostate tissue.
Found at: doi:10.1371/journal.pone.0014175.s013 (2.40 MB
TIF)
Figure S3 Sarcosine levels in bone metastases. A. Box plot for
sarcosine concentration showing significantly higher levels in
prostate cancer (PCa) bone metastases compared to normal bone.
B. Box plot for sarcosine in test set showing higher levels in PCa
bone metastases compared to normal bone but no difference in
levels in PCa bone metastases compared to bone metastases from
other cancers; breast, kidney, and squamous cancer (BCa, KCa
and SCa).
Found at: doi:10.1371/journal.pone.0014175.s014 (4.93 MB
TIF)
Data S1
Found at: doi:10.1371/journal.pone.0014175.s015 (0.38 MB
XLS)
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